

DEAL PROFILE

FRESENIUS | AKORN

VALUES

\$4.9bn

10.6x

4.4x

TRANSACTION VALUE

LTM EBITDA MULTIPLE

LTM REVENUE MULTIPLE



FRESENIUS SE & CO. KGaA (DB: FRE)

Fresenius SE & Co. (“Fresenius”) is a diversified global healthcare group based in Germany. The company’s offering includes high-quality products and services for dialysis, hospitals, pharmaceutical products, medical devices and outpatient treatments.

TEV: \$69.2bn

LTM EBITDA: \$5.92bn

LTM Revenue: \$31.58bn



AKORN, INC. (NASDAQ: AKRX)

Akorn, Inc. (“Akorn”) is a specialty generic pharmaceutical company that develops, manufactures, and markets generic and branded pharmaceutical products. The company also has small private-label over-the-counter (“OTC”) and animal health businesses is a specialty generic pharmaceutical company that develops, manufactures, and markets generic and branded pharmaceutical products. The company also has small private-label OTC and animal health businesses.

IEV: \$4.9bn

LTM EBITDA: \$406m

LTM Revenue: \$1.12bn

BOURNE PARTNERS MARKET RESEARCH

Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution life cycle. In order to provide the highest level of service, we routinely analyze relevant industry trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, OTC, consumer health, and biotechnology sectors.

OVERVIEW

Fresenius announced on April 25th, 2017, that it has agreed to acquire Akorn, a specialized generic pharmaceutical manufacturer, for \$4.3 billion. Akorn will be integrated within Fresenius’ Fresenius Kabi division which is focused on I.V. generic drugs, infusion therapies and clinical nutrition products.

HIGHLIGHTS

Fresenius will fund the acquisition with debt, paying \$34.00 per share in cash for the company. The acquisition is expected to be accretive to 2018 earnings excluding integration costs and accretive to 2019 earnings including integration costs. The deal will further build-out Fresenius’ specialized pharmaceutical product offering, while offering access to new distribution channels such as retail pharmacies. This additional access is expected to help drive growth in the companies recently acquired portfolio of biosimilar assets from Merck KGaA. The transaction is expected to close by early 2018.